Amylyx Pharmaceuticals Announces Pricing of Upsized Initial Public Offering of Common Stock

January 6, 2022

CAMBRIDGE, Mass.--(BUSINESS WIRE)-- Amylyx Pharmaceuticals, Inc. (“Amylyx”), a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases, today announced the pricing of its upsized initial public offering of 10,000,000 shares of common stock pursuant to registration statements on Form S-1 filed with the U.S. Securities and Exchange Commission (“SEC”) at an initial public offering price of $19.00 per share.

All of the shares of common stock are being offered by Amylyx. Amylyx has granted the underwriters a 30-day option to purchase up to an additional 1,500,000 shares of common stock at the initial public offering price, less underwriting discounts and commissions. The gross proceeds to Amylyx from this offering are expected to be $190 million, before deducting underwriting discounts and commissions and offering expenses and excluding any exercise of the underwriters' option to purchase additional shares.

Amylyx' common stock is expected to begin trading on the Nasdaq Global Select Market under the ticker symbol "AMLX" on January 7, 2022. The offering is expected to close on or about January 11, 2022, subject to the satisfaction of customary closing conditions.

Goldman Sachs & Co. LLC, SVB Leerink, and Evercore ISI are acting as joint book-running managers for the offering. H.C. Wainwright & Co. is acting as lead manager for the offering.

Registration statements on Form S-1 relating to these securities were declared effective by the SEC on January 6, 2022. The offering is being made only by means of a prospectus. Copies of the final prospectus relating to the offering, may be obtained, when available, from: Goldman Sachs & Co. LLC, at Prospectus Department, 200 West Street, New York, New York 10282, by telephone at 1-866-471-2526 or by e-mail at prospectus-ny@ny.email.gs.com; SVB Leerink LLC, Attention: Syndicate Department, 53 State Street, 40th Floor, Boston, Massachusetts 02109, by telephone at 1-800-808-7525, ext. 6105, or by email at syndicate@svbleerink.com; or Evercore Group L.L.C., Attention: Equity Capital Markets, 55 East 52nd Street, 35th Floor, New York, New York 10055, by telephone at 1-888-474-0200, or by email at ecm.prospectus@evercore.com.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction.

About Amylyx Pharmaceuticals
Amylyx Pharmaceuticals, Inc. is a clinical-stage pharmaceutical company working on developing a novel therapeutic for amyotrophic lateral sclerosis (ALS) and other neurodegenerative diseases.

Forward-Looking Statements
Statements contained in this press release regarding matters that are not historical facts are “forward-looking statements”, including with respect to the offering. No assurance can be given that the offering discussed above will be completed. Because such statements are subject to risks and uncertainties, actual results may differ materially from those expressed or implied by such forward-looking statements. Any forward-looking statements in this statement are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. Risks that contribute to the uncertain nature of the forward-looking statements include those risks and uncertainties set forth in Amylyx’ registration statements on Form S-1 filed with the United States Securities and Exchange Commission and the preliminary prospectus included therein. Copies of the registration statements can be accessed by visiting the Securities and Exchange Commission website at www.sec.gov. All forward-looking statements contained in this press release speak only as of the date on which they were made. Amylyx undertakes no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they were made.

Media
Becky Gohsler
Finn Partners
(646) 307-6307

Becky.Gohsler@finnpartners.com

Investors
James Frates
Amylyx Pharmaceuticals
(857) 320-6230
Jim_Frates@amylyx.com

Source: Amylyx Pharmaceuticals, Inc.